Lv51
1060 积分 2022-09-21 加入
Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor
6天前
已完结
Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
6天前
已完结
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma
6天前
已完结
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
14天前
已完结
Fibroblast growth factor receptor 2: a new potential therapeutic target for human cancer
17天前
已完结
Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis
17天前
已完结
Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
17天前
已完结
Discovery of BW710 as a Potent, Selective and Orally Bioavailable Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitor
19天前
已完结
FGFR2 in the Development and Progression of Cutaneous Squamous Cell Cancer
24天前
已完结
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
24天前
已完结
皖公网安备34019202002308
